EUVIMEDEUVIMED entdecken
Crossref

Pituitary dysfunction after cranial radiotherapy for brain tumor

Julie Chapon, Julien Berthillier, Amna Klich, Ronan Tanguy, Nathalie Perreton, Pauline Drouin, Aude Brac-de-la-Perrière, Chantal Simonet, Helene Lasolle, Gerald Raverot, Fabien Subtil, Françoise Borson-Chazot

Annales d'Endocrinologie · 2025

DOI: 10.1016/j.ando.2025.101722 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annales d'Endocrinologie, 2025. Verfasst von Julie Chapon und 11 weiteren Autor:innen. Beteiligte Einrichtung: Fédération d'endocrinologie, centre de référence des maladies rares hypophysaires (HYPO), hôpital Louis-Pradel, Groupement Hospitalier Est, hospices …. Hauptthemen laut MEDLINE: Brain Neoplasms, Cranial Irradiation, Radiation Injuries, Pituitary Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Novo Nordisk, Novo Nordisk Pharma Co Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cranial radiotherapy for extrapituitary brain tumor is a rare cause of acquired pituitary deficiency. The main objective of the present study was to evaluate the incidence and time onset of pituitary deficit and to investigate predictive factors. MATERIAL AND METHODS: This retrospective cohort study included 246 patients referred to our endocrinology department between 2005 and 2021 for hormone testing after radiotherapy for extrapituitary brain tumor. Incidence of pituitary deficit was reported with 95% confidence intervals [95% CI]. Deficit-free survival was estimated on the Kaplan Meier method. RESULTS: Mean (SD) age at inclusion was 32.2 years (20.3). One hundred and forty-one patients were male (57.3%). One hundred and seventy-five (71.1%) were irradiated after and 71 (28.9%) at or before the age of 15. Mean (SD) follow-up was 10 years (7). At the end of the study, 118 patients (48.0%) had ≥1 hormonal deficit: GH deficit in 88 patients (36.5%), TSH deficit in 61 (24.8%), LH/FSH deficit in 47 (19.5%); ACTH deficit was identified in 12 patients (4.9%), and was never isolated. The overall incidence of pituitary deficits was 10.3 per 100 person-years (95% CI [30.8; 65.3]) and did not differ according to age at irradiation. Pituitary deficits occurred within a mean (SD) 2.6 years (2.5), 4.9 years (3.3), 4.0 years (2.4) and 4.8 years (3.1) for ACTH, TSH, GH and LH/FSH, respectively. The only factor associated with deficit-free survival was pituitary gland D50 (maximum dose received by at least 50% of gland volume): D50 37-44Gy compared to 1-24Gy; HR: 2.51; 95% CI [1.09; 5.80]; P=0.031. CONCLUSION: Half of the patients presented pituitary deficits 10 years after irradiation for extrapituitary brain tumor. However, ACTH deficit was rare, and never isolated, suggesting that it is not necessary to carry out a dynamic test for ACTH if no other deficits are diagnosed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsCranial IrradiationRadiation InjuriesPituitary DiseasesHypopituitarismPituitary GlandHumansMaleFemaleRetrospective StudiesAdultMiddle AgedYoung AdultAdolescentIncidenceChildAged

Stichwörter der Autor:innen

Brain tumorCancer survivorHypothalamic-pituitary dysfunctionLate endocrine effectRadiotherapy

Autor:innen und Institutionen

  • Fédération d'endocrinologie, centre de référence des maladies rares hypophysaires (HYPO), hôpital Louis-Pradel, Groupement Hospitalier Est, hospices civils de Lyon, 59, boulevard Pinel, Bron, France; Université Claude-B…
  • Service de recherche et d'épidémiologie clinique, Pôle de santé publique, hospices civils de Lyon, Lyon, France.
  • Service de biostatistique, hospices civils de Lyon, Lyon, France.
  • Service de radiothérapie, centre Léon-Bérard, 28, promenade Léa et Napoléon-Bullukian, Lyon, France.
  • Fédération d'endocrinologie, centre de référence des maladies rares hypophysaires (HYPO), hôpital Louis-Pradel, Groupement Hospitalier Est, hospices civils de Lyon, 59, boulevard Pinel, Bron, France.
  • Université Claude-Bernard, Lyon 1, Lyon, France; Service de biostatistique, hospices civils de Lyon, Lyon, France.

Förderung

  • Novo Nordisk
  • Novo Nordisk Pharma Co Ltd

Zitieren

APA

Chapon, J., Berthillier, J., Klich, A., Tanguy, R., Perreton, N., Drouin, P., Brac-de-la-Perrière, A., Simonet, C., Lasolle, H., Raverot, G., Subtil, F., & Borson-Chazot, F. (2025). Pituitary dysfunction after cranial radiotherapy for brain tumor. Annales d'Endocrinologie. https://doi.org/10.1016/j.ando.2025.101722

Vancouver

Chapon J, Berthillier J, Klich A, Tanguy R, Perreton N, Drouin P, et al. Pituitary dysfunction after cranial radiotherapy for brain tumor. Annales d'Endocrinologie. 2025. doi:10.1016/j.ando.2025.101722

BibTeX
@article{Chapon2025,
  author = {Chapon, Julie and Berthillier, Julien and Klich, Amna and Tanguy, Ronan and Perreton, Nathalie and Drouin, Pauline and Brac-de-la-Perrière, Aude and Simonet, Chantal and Lasolle, Helene and Raverot, Gerald and Subtil, Fabien and Borson-Chazot, Françoise},
  title = {Pituitary dysfunction after cranial radiotherapy for brain tumor},
  journal = {Annales d'Endocrinologie},
  year = {2025},
  doi = {10.1016/j.ando.2025.101722}
}
Kostenlos starten →